Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

Study; and the use of pharmacotherapy to treat obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the complete study report for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen's ability to conduct the Light Study and the progress and timing thereof, including risks associated with enrolling and retaining the appropriate patients in the Light Study; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese patients treated with Contrave does not adversely affect Contrave's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE data; the potential for the Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with Takeda Pharmaceutical Company Limited; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; the development plan for Empatic; Orexigen's ability to enter into a collaborative partnersh
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 28, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Cardiovascular Drug Delivery ... offering. Drug delivery to the cardiovascular ... because of the anatomy and physiology of the ... all organs of the body. Drugs can be ...
(Date:5/29/2015)... and BOSTON , May ... in instrument development, custom automation, and contract manufacturing, and ... the Nanopatch™ needle-free drug delivery technology, have been named ... of the Nanopatch Jet Coating Instrument , an ... research and product development.  The award was announced last ...
(Date:5/29/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... American Association of Cancer Research (AACR) Advances in ... for its lead product candidate VAL-083 ...
Breaking Medicine Technology:Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
... Sept. 16 Wound Management Technologies, Inc. (OTC ... that its subsidiary, Wound Care Innovations, L.L.C. (WCI), ... (Bivium) to distribute its advanced wound care collagen ... be introducing Cellerate RX® to the Panamian health-care ...
... 16 Roche Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) ... of STAT immunoassays for cardiac biomarker testing on the ... designed for diagnostic labs with medium testing volumes. With ... other cardiac immunoassay tests currently available on an integrated ...
Cached Medicine Technology:Wound Management Technologies Adds Panama to Growing List of Distribution Points in Central America 2Wound Management Technologies Adds Panama to Growing List of Distribution Points in Central America 3Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series 2Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series 3
(Date:5/30/2015)... 2015 This year the National ... Horizons to offer one of the most diverse perspectives ... successful practices to diagnose, treat and manage patients with ... Horizons Conference is Interaction with Multidisciplinary Healthcare Professionals ... Needs of Patients with COPD," said Brian W. Carlin, ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 Venus Viva ... acne scars, large pores, deep wrinkles, stretch marks, pigmentation ... medical professional, such as Dr. F. Victor Rueckl of ... the clinical trials in Las Vegas. This body image ... into a system that delivers proven results through a ...
(Date:5/29/2015)... “In the current environment of ... regulations, we provide education that will help practitioners ... suffering from pain, within the boundaries of the ... of rehabilitation medicine and President/Medical Director of the ... , A new flight of PAINWeekEnd Regional Conferences ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 What does ... The Denver Foundation, community comes together to plant gardens, ... build neighborhoods and awareness of critical issues. Community invites ... Denver and beyond. , "What Community Does" was commissioned ... foundation in Colorado, and released during the foundation’s Annual ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The third ... The event, now closed to new registration, starts outside ... This exciting competitive running event demonstrates the power ... create a public benefit – in this case, historic ... views around the famed Ocean Drive and passes by ...
Breaking Medicine News(10 mins):Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3
... who had "Tommy John" elbow reconstruction surgery were able to ... to a study released today at the 2008 American Orthopaedic ... Grande Lakes. While reassuring to athletes, the study authors find ... surgery, alarming. , "Before 1997 this surgery was performed on ...
... (CDH) of Winfield, Ill. has been ranked #47 in ... accessible today online,at http://www.usnews.com/besthospitals and on sale ... 5,453 hospitals reviewed, only 170 medical centers,nationwide ranked high ... listed in one or more of the 16 specialties., ...
... 11 In a letter to the,Senate, forty-five ... to address critical shortfalls in legislation that would,reauthorize ... the Senate,poised to vote on a five-year, $50 ... to "both set and correct policies based,on evidence ...
... Calif., July 11 A,democratic process involving several SEIU ... with hearings to determine the best way to unite,long-term ... greatest strength,to win for their families and the clients ... a thorough, open, and democratic,discussion to make sure that ...
... no difference, study finds , , FRIDAY, July 11 (HealthDay ... developing breast cancer do not seem to improve even ... the disease, a new report says. , Scientists have ... small but statistically significant increase in the risk of ...
... Zen at Zoe's Garden, a new Baltimore wellness center offering massage ... in Fells Point. , ... Baltimore, MD (PRWEB) July ... wellness center offering massage therapy, acupuncture, yoga instruction , ...
Cached Medicine News:Health News:Dramatic increase in 'Tommy John' surgery in young patients cause for concern 2Health News:Central DuPage Hospital's Orthopedics Ranks in U.S. News Media Group's 2008 Edition of America's Best Hospitals for the Second Consecutive Year 2Health News:Central DuPage Hospital's Orthopedics Ranks in U.S. News Media Group's 2008 Edition of America's Best Hospitals for the Second Consecutive Year 3Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 2Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 3Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 4Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 5Health News:Recent Genetic Discoveries Don't Improve Prediction of Breast Cancer 2Health News:Baltimore Wellness Center "Zen at Zoe's Garden" Launches in Baltimore's Fells Point 2
Spurling-Kerrison (Colclough) Laminectomie Rongeur. 15 cm - 6, thick footplate, large handle, 40 up-cutting, jaws 3 mm wide....
Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide....
... The Tangent Posterior Impacted Instrument Set offers ... of the advantages offered by the Tangent ... preparation and the ability to reproduce the ... to ensure proper vertebral body distraction. A ...
Regulates physiological flow within normal ranges of Intraventricular Pressure (IVP) in the supine, sitting or standing position....
Medicine Products: